Nabil Noureddin1, Mazen Noureddin2, Amandeep Singh3, Naim Alkhouri4. 1. Department of Medicine, University of Nevada Las Vegas, Las Vegas, NV, USA. 2. Cedars-Sinai Fatty Liver Program, Division of Digestive and Liver Diseases, Department of Medicine, Comprehensive Transplant Center, Cedars-Sinai Medical Center, Los Angeles, CA, USA. 3. Digestive Disease and Surgery Institute, Cleveland Clinic, Cleveland, OH, USA. 4. Fatty Liver Program, VP of Academic Affairs, Arizona Liver Health, 2201 Fairview Street, Suite 9, Phoenix, AZ, USA. nalkhouri@azliver.com.
Abstract
BACKGROUND: Nonalcoholic fatty liver disease (NAFLD) can progress to advanced fibrosis, especially in patients with type 2 diabetes. Small studies have shown that fibrosis can also regress. AIM: We aimed to provide large-scale data on progression and regression of fibrosis in diabetics with NAFLD. METHODS: Adult diabetic patients with the diagnosis of NAFLD based on ICD-9 codes were identified. We used scores from noninvasive tests to identify patients with advanced fibrosis, calculated at first assessment and last follow-up visit. Cutoff values for advanced fibrosis were AST: ALT ratio > 1.4, AST to platelet ratio index > 1.5, FIB-4 score > 2.67, and NAFLD fibrosis score > 0.676. RESULTS: Our cohort included 50,695 diabetics with NAFLD (55.3% female; 71% Caucasian; mean age, 51.2 ± 11.6 y). During median follow-up of 84.4 months, 25.8% transitioned from no advanced fibrosis to advanced fibrosis (progression), 6.4% transitioned from advanced fibrosis to no advanced fibrosis (regression), and the rest remained stable. Factors associated with transition to advanced fibrosis were female sex, older age at first evaluation, African-American race, obesity, chronic kidney disease, or coronary artery disease. Use of insulin increased the risk of progression to advanced fibrosis (odds ratio,1.36; p < .001), whereas use of oral hypoglycemic agents, angiotensin 2 receptor blockers, and fibrates was associated with reduced risk (odds ratios, 0.92, 0.94 and 0.90, respectively; all p < .05). CONCLUSIONS: In a large cohort of patients with type 2 diabetes and NAFLD, more than a quarter progressed to advanced fibrosis. These findings indicate the need for early detection and staging of NAFLD in diabetics.
BACKGROUND: Nonalcoholic fatty liver disease (NAFLD) can progress to advanced fibrosis, especially in patients with type 2 diabetes. Small studies have shown that fibrosis can also regress. AIM: We aimed to provide large-scale data on progression and regression of fibrosis in diabetics with NAFLD. METHODS: Adult diabetic patients with the diagnosis of NAFLD based on ICD-9 codes were identified. We used scores from noninvasive tests to identify patients with advanced fibrosis, calculated at first assessment and last follow-up visit. Cutoff values for advanced fibrosis were AST: ALT ratio > 1.4, AST to platelet ratio index > 1.5, FIB-4 score > 2.67, and NAFLD fibrosis score > 0.676. RESULTS: Our cohort included 50,695 diabetics with NAFLD (55.3% female; 71% Caucasian; mean age, 51.2 ± 11.6 y). During median follow-up of 84.4 months, 25.8% transitioned from no advanced fibrosis to advanced fibrosis (progression), 6.4% transitioned from advanced fibrosis to no advanced fibrosis (regression), and the rest remained stable. Factors associated with transition to advanced fibrosis were female sex, older age at first evaluation, African-American race, obesity, chronic kidney disease, or coronary artery disease. Use of insulin increased the risk of progression to advanced fibrosis (odds ratio,1.36; p < .001), whereas use of oral hypoglycemic agents, angiotensin 2 receptor blockers, and fibrates was associated with reduced risk (odds ratios, 0.92, 0.94 and 0.90, respectively; all p < .05). CONCLUSIONS: In a large cohort of patients with type 2 diabetes and NAFLD, more than a quarter progressed to advanced fibrosis. These findings indicate the need for early detection and staging of NAFLD in diabetics.
Authors: Leon A Adams; Scott Harmsen; Jennifer L St Sauver; Phunchai Charatcharoenwitthaya; Felicity B Enders; Terry Therneau; Paul Angulo Journal: Am J Gastroenterol Date: 2010-02-09 Impact factor: 10.864
Authors: Christopher D Williams; Joel Stengel; Michael I Asike; Dawn M Torres; Janet Shaw; Maricela Contreras; Cristy L Landt; Stephen A Harrison Journal: Gastroenterology Date: 2010-09-19 Impact factor: 22.682
Authors: Stuart McPherson; Tim Hardy; Elsbeth Henderson; Alastair D Burt; Christopher P Day; Quentin M Anstee Journal: J Hepatol Date: 2014-12-01 Impact factor: 25.083
Authors: Raj Vuppalanchi; Mohammad S Siddiqui; Mark L Van Natta; Erin Hallinan; Danielle Brandman; Kris Kowdley; Brent A Neuschwander-Tetri; Rohit Loomba; Srinivas Dasarathy; Manal Abdelmalek; Edward Doo; James A Tonascia; David E Kleiner; Arun J Sanyal; Naga Chalasani Journal: Hepatology Date: 2017-11-29 Impact factor: 17.425
Authors: Rachel M Williamson; Jackie F Price; Stephen Glancy; Elisa Perry; Lisa D Nee; Peter C Hayes; Brian M Frier; Liesbeth A F Van Look; Geoffrey I Johnston; Rebecca M Reynolds; Mark W J Strachan Journal: Diabetes Care Date: 2011-04-08 Impact factor: 19.112